Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares - CANF STOCK NEWS

Can-Fite BioPharma Ltd (NYSE American: CANF) has secured approximately $20 million from partnering deals, with potential for an additional $130 million in milestone payments and royalties. The company will participate in three upcoming virtual conferences to meet with potential partners for its drug candidates targeting cancer, liver diseases, and inflammation. Key events include BioPharm America 2021 (Sept 20-23), TAP Diabetes 2021 (Oct 5-7), and BIO-Europe 2021 (Oct 25-29). Can-Fite's leading candidates are in advanced clinical stages.

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will focus on the company's proprietary small molecule drugs aimed at inflammatory, cancer, and liver diseases, with a special emphasis on Piclidenoson and Namodenoson, which are advancing through various clinical trials. The presentation will be available on the conference portal at 7:00 AM ET on September 13.

Can-Fite BioPharma has completed enrollment of over 400 patients for its Phase III Comfort™ study targeting moderate to severe plaque psoriasis. The study follows a positive interim analysis from October 2020, which recommended continuation based on data from 200 patients. Topline results are anticipated in Q1 2022. This randomized, double-blind study is being conducted in Europe, Israel, and Canada, with primary endpoints focused on patient response rates. Can-Fite’s lead candidate, Piclidenoson, aims to offer an effective oral treatment alternative in a growing $11.3 billion market by 2025.

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced its financial results for Q2 2021. The company reported immaterial revenue decline to $0.39 million compared to $0.40 million in Q2 2020. Notable developments include a $3 billion commercialization agreement for Piclidenoson in veterinary osteoarthritis and a Notice Allowance for a NASH patent in China. The net loss decreased to $5.09 million from $8.23 million year over year. Can-Fite has approximately $7.5 million in cash while anticipating significant milestones in upcoming studies.

Can-Fite BioPharma Ltd. (NYSE: CANF) has signed a definitive agreement with a healthcare-focused institutional investor to sell 5,000,000 American Depositary Shares (ADSs) at $2.00 each, raising gross proceeds of $10 million for research, development, and working capital. A concurrent private placement of warrants to purchase up to 5,000,000 ADSs will also occur at the same price. The offering, expected to close around August 16, 2021, is facilitated by H.C. Wainwright & Co. The ADSs are offered under a shelf registration statement filed with the SEC.

Can-Fite BioPharma Ltd. (NYSE American: CANF) has appointed Yossi Borenstein as an External Director during its recent annual general meeting. Borenstein, CEO of Shizim Group and a veteran in the Israeli biomed industry, brings over 35 years of experience, having previously managed Bristol-Myers Squibb (Israel) and served in various leadership roles across multiple organizations. Can-Fite, engaged in developing therapies for cancer, liver, and inflammatory diseases, continues its clinical progress with drug candidates like Piclidenoson and Namodenoson.

Can-Fite BioPharma Ltd (NYSE: CANF) has completed preparatory work for its pivotal Phase III trial of Namodenoson, targeting hepatocellular carcinoma (HCC), the most prevalent liver cancer. The trial will enroll 450 patients globally and is designed to assess overall survival and safety. Both the FDA and EMA have agreed to the trial protocol, and Namodenoson has received Orphan Drug and Fast Track designations. This advancement comes amid a global market for HCC treatments projected to reach $3.8 billion by 2027.

Can-Fite BioPharma (NYSE: CANF) has entered a development and commercialization agreement with Vetbiolix for its drug, Piclidenoson, targeting osteoarthritis in pets. Vetbiolix will conduct proof-of-concept studies over two years, covering all associated costs, and may obtain a license for further development if the data is positive. The canine osteoarthritis market is projected to reach $3 billion by 2024, with the broader companion animal health market expected to grow to $27 billion by 2028. Piclidenoson offers a potentially effective oral treatment alternative to existing NSAIDs.

Can-Fite BioPharma Ltd (NYSE American: CANF) announced that the Chinese National Intellectual Property Administration granted a Notice of Allowance for its patent on an A3 Adenosine Receptor ligand aimed at treating ectopic fat accumulation. This patent supports their liver drug candidate, Namodenoson, which is set to enter Phase IIb trials for non-alcoholic steatohepatitis (NASH) in Q3 2021, following successful Phase IIa results. Namodenoson has been licensed in China with potential milestone payments of up to $74.5 million. The NASH market in China is projected to reach $6.4 billion by 2027.